Abstract Number: 1886 • 2019 ACR/ARP Annual Meeting
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Background/Purpose: Novel antibody systems including anti-carbamylated protein antibody (anti-CarP IgG) and anti-peptidyl arginine deiminase antibody (anti-PAD4 IgG) are emerging as independent diagnostic and prognostic biomarkers…Abstract Number: 1998 • 2019 ACR/ARP Annual Meeting
Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use
Background/Purpose: Shared epitope smoking interaction does not fully explain MHC association in Rheumatoid Arthritis (RA). We have previously shown HLA-DQB1*0601 (DQ6.1) to be a susceptibility…Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…Abstract Number: 2288 • 2019 ACR/ARP Annual Meeting
Pregnancy Outcomes in Women Exposed to Golimumab
Background/Purpose: Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic…Abstract Number: 2320 • 2019 ACR/ARP Annual Meeting
Knowledge of Cardiovascular Disease Risk Among Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a significantly higher risk of cardiovascular disease (CVD) than general population. The Heart Disease Fact Questionnaire (HDFQ-RA 1…Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…Abstract Number: 2364 • 2019 ACR/ARP Annual Meeting
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
Background/Purpose: Lymphoproliferative disorders (LPD) remains as a major problem to resolve among the patients with rheumatoid arthritis (RA). During few decades, rheumatic therapy has dramatically…Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…Abstract Number: 2772 • 2019 ACR/ARP Annual Meeting
Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet
Background/Purpose: RA patients often inquire about dietary interventions to improve disease control, as they perceive quick changes in pain and/or swelling after consumption of certain…Abstract Number: 2872 • 2019 ACR/ARP Annual Meeting
Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or…Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…Abstract Number: 117 • 2019 ACR/ARP Annual Meeting
The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovium, which causes progressive joint destruction and reduction in quality of life.…Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…Abstract Number: 315 • 2019 ACR/ARP Annual Meeting
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…Abstract Number: 454 • 2019 ACR/ARP Annual Meeting
Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study
Background/Purpose: Determining the prognosis of rheumatoid arthritis (RA) could guide more precise treatment selection, optimizing outcomes while minimizing unnecessary therapeutic exposures. It is important that…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 56
- Next Page »